NCT03814447View on ClinicalTrials.gov

The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 16, 2019

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions
Ovarian Cancer
Interventions
DRUG

anti- MESO CAR-T cells

Autologous genetically modified anti- MESO CAR transduced T cells

DRUG

Fludarabine

Dose: 30mg/m2/d

DRUG

Cyclophosphamide

Dose: 300mg/m2/d

Trial Locations (1)

Unknown

RECRUITING

Shanghai 6th People's Hospital, Shanghai

Sponsors
All Listed Sponsors
collaborator

Hrain Biotechnology Co., Ltd.

INDUSTRY

lead

Shanghai 6th People's Hospital

OTHER